Spots Global Cancer Trial Database for monomethyl auristatin e
Every month we try and update this database with for monomethyl auristatin e cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma | NCT01060904 | Disease, Hodgki... | brentuximab ved... doxorubicin vinblastine dacarbazine bleomycin brentuximab ved... | 18 Years - 60 Years | Seagen Inc. | |
| Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies | NCT01461538 | Acute Lymphoid ... Acute Myeloid L... Anemia, Refract... Solid Tumors | brentuximab ved... brentuximab ved... brentuximab ved... | 6 Years - | Seagen Inc. | |
| A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma | NCT02572167 | Hodgkin Lymphom... | brentuximab ved... nivolumab | 18 Years - | Seagen Inc. | |
| A Safety Study of SGN-LIV1A in Breast Cancer Patients | NCT01969643 | HER2 Positive B... Hormone Recepto... Triple Negative... HER2 Mutations ... | ladiratuzumab v... Trastuzumab | 18 Years - | Seagen Inc. | |
| Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35) | NCT01026415 | Carcinomas Disease, Hodgki... Lymphoma, Large... Lymphoma, Non-H... Neoplasms | brentuximab ved... rifampin midazolam ketoconazole brentuximab ved... | 18 Years - | Seagen Inc. | |
| A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma | NCT01060904 | Disease, Hodgki... | brentuximab ved... doxorubicin vinblastine dacarbazine bleomycin brentuximab ved... | 18 Years - 60 Years | Seagen Inc. | |
| A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma | NCT01060904 | Disease, Hodgki... | brentuximab ved... doxorubicin vinblastine dacarbazine bleomycin brentuximab ved... | 18 Years - 60 Years | Seagen Inc. | |
| A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma | NCT01421667 | Lymphoma, B-Cel... Lymphoma, Large... Lymphoma, Non-H... Lymphoma, T-Cel... | brentuximab ved... rituximab | 6 Years - | Seagen Inc. | |
| A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma | NCT02572167 | Hodgkin Lymphom... | brentuximab ved... nivolumab | 18 Years - | Seagen Inc. | |
| A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma | NCT00866047 | Lymphoma, Large... Lymphoma, Non-H... | brentuximab ved... | 12 Years - | Seagen Inc. | |
| Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35) | NCT01026415 | Carcinomas Disease, Hodgki... Lymphoma, Large... Lymphoma, Non-H... Neoplasms | brentuximab ved... rifampin midazolam ketoconazole brentuximab ved... | 18 Years - | Seagen Inc. | |
| A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms | NCT01309789 | Lymphoma, Large... Lymphoma, NK-ce... Lymphoma, T-cel... | brentuximab ved... cyclophosphamid... brentuximab ved... prednisone cyclophosphamid... doxorubicin doxorubicin prednisone vincristine | 18 Years - | Seagen Inc. | |
| Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies | NCT01461538 | Acute Lymphoid ... Acute Myeloid L... Anemia, Refract... Solid Tumors | brentuximab ved... brentuximab ved... brentuximab ved... | 6 Years - | Seagen Inc. | |
| A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma | NCT01950364 | Hodgkin Lymphom... Anaplastic Larg... | brentuximab ved... Brentuximab ved... | 18 Years - 75 Years | Millennium Pharmaceuticals, Inc. | |
| ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas | NCT01777152 | Anaplastic Larg... Non-Hodgkin Lym... T-Cell Lymphoma | brentuximab ved... doxorubicin prednisone vincristine cyclophosphamid... | 18 Years - | Seagen Inc. | |
| A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma | NCT01990534 | Hodgkin Lymphom... | Brentuximab Ved... | 18 Years - | Takeda | |
| A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms | NCT01309789 | Lymphoma, Large... Lymphoma, NK-ce... Lymphoma, T-cel... | brentuximab ved... cyclophosphamid... brentuximab ved... prednisone cyclophosphamid... doxorubicin doxorubicin prednisone vincristine | 18 Years - | Seagen Inc. | |
| A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma | NCT01060904 | Disease, Hodgki... | brentuximab ved... doxorubicin vinblastine dacarbazine bleomycin brentuximab ved... | 18 Years - 60 Years | Seagen Inc. | |
| Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL) | NCT01925612 | Lymphoma, B-cel... Lymphoma, Large... | brentuximab ved... brentuximab ved... rituximab vincristine cyclophosphamid... prednisone doxorubicin | 18 Years - | Seagen Inc. | |
| A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma | NCT01421667 | Lymphoma, B-Cel... Lymphoma, Large... Lymphoma, Non-H... Lymphoma, T-Cel... | brentuximab ved... rituximab | 6 Years - | Seagen Inc. | |
| A Safety Study of SGN-LIV1A in Breast Cancer Patients | NCT01969643 | HER2 Positive B... Hormone Recepto... Triple Negative... HER2 Mutations ... | ladiratuzumab v... Trastuzumab | 18 Years - | Seagen Inc. | |
| A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies | NCT00649584 | Disease, Hodgki... Lymphoma, Large... Lymphoma, Non-H... | SGN-35 gemcitabine | 12 Years - | Seagen Inc. | |
| Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies | NCT01461538 | Acute Lymphoid ... Acute Myeloid L... Anemia, Refract... Solid Tumors | brentuximab ved... brentuximab ved... brentuximab ved... | 6 Years - | Seagen Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
